Extracorporeal membrane oxygenation (ECMO) during aplasia: A bridge towards myopericarditis recovery after autologous hematopoietic stem cell transplant for systemic sclerosis and recent Coronarovirus disease (COVID-19) vaccination

This report illustrates, for the first time to our knowledge, that ECMO can be indicated despite aplasia during aHSCT and successfully used as a bridge towards heart function recovery in highly selected and fragile AD patients. We review the factors that may contribute to endothelial and myocardial stunning and acute reversible cardiac failure in SSc and aggravate intrinsic endothelial injury during the aHSCT procedure. These classically include: cyclophosphamide drug toxicity, viral infections and autoimmune activation with disease flair per se. In the COVID-19 pandemic times, acute myocarditis due to recent viral infection or mRNA vaccine per se, must also be considered.PMID:38636307 | DOI:10.1016/j.retram.2024.103449

Source: Cell Research - April 18, 2024 Category: Cytology Authors: Carlotta Cacciatore Mathilde Baudet Estelle Jean Simona Presente Marylou Para Romain Sonneville Dimitri Arangalage Nassim Ait Abdallah Flore Sicre de Fontbrune Pedro Henrique Prata Benjamin Crichi Baptiste Hervier Nathalie Parquet Gilles Soulat Elie Mouss Source Type: research